Zentalis Pharmaceuticals awards stock options to new employees under 2022 Inducement Plan

SAN DIEGO, Sept. 01, 2026 /CourierPR/ -- Zentalis Pharmaceuticals, a clinical oncology innovator, has expanded its workforce by awarding non-qualified stock options to four newly hired employees. The grants, totaling 269,000 shares, were made on September 1, 2026, under the company’s 2022 Employment Inducement Incentive Award Plan, as per Nasdaq Listing Rule 5635(c)(4).

According to the terms of the 2022 Inducement Plan, these equity awards are designed to incentivize the hiring of new employees by providing them with stock options as a form of inducement. Each option allows the recipients to purchase shares at an exercise price of $3.71, the closing price of Zentalis common stock on the date of grant. The options carry a 10-year term and will vest over four years, with 25% vesting on the first anniversary of the vesting commencement date, followed by monthly installments over the subsequent three years.

The stock options are subject to the employees' continued service to Zentalis on each vesting date, ensuring alignment between the company and its new team members. Zentalis, known for its WEE1 inhibitor azenosertib, continues to leverage its expertise in therapeutics development and biomarker science to advance its pipeline.

Founded as a clinical oncology innovator, Zentalis focuses on developing first-in-class treatments. The company's approach includes both monotherapy and combination studies of azenosertib, a WEE1 inhibitor, with the goal of enhancing treatment options and outcomes for cancer patients. "Our mission is to provide more convenient and effective care to cancer patients," Feingold added.